Davita Inc vs Remitly Global Inc — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while Remitly Global Inc trades at $23.42 (market cap $4.98B). The key difference: Davita Inc is far larger — about 2.3× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Remitly Global Inc for 53 Days on average.
| DVA | RELY | |
|---|---|---|
Market Cap | $11.29B | $4.98B |
Volume | 582,204 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $240.96 | $26.92 |
52-Week Low | $103.87 | $12.20 |
Typical Hold Time | 113 Days | 53 Days |
Enterprise Value | $24.01B | $4.34B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with Q2 2026 revenue growth of 20% to $495 million and three consecutive quarterly EPS beats. Analyst consensus is strongly bullish with a $30.50 price target, supported by expanding profit margins and active customer growth exceeding 10 million.
Outlook remains positive given robust revenue growth and profitability expansion, but risks include competitive pressures in fintech and reliance on continued customer acquisition. The stock offers upside to analyst targets, though volatility may persist amid market shifts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →